Synthesis, antiproliferative screening, and molecular docking of some heterocycles derived from N-(1-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-hydrazineyl-3-oxoprop-1-en-2-yl)benzamide
Evaluation shows significant cytotoxic activity of heterocycles against breast and colon cancer, suggesting potential as CDK2 inhibitors.
Key Points
Compounds demonstrated notable cytotoxic activity against colon cancer (HCT-116) and breast cancer (MCF-7) cell lines, indicating their potential for targeted cancer therapy.
Among compounds tested, those 5, 8, 9, and 10 particularly exhibited significant antiproliferative activity, highlighting their relevance in cancer treatment.
Molecular docking revealed that compound 9 had the highest binding score of -9.5080 kcal/mol, surpassing that of doxorubicin, indicating strong interaction potential with related proteins.
Heterocycles derived from the synthesized hydrazide exhibited selective toxicity, implying enhanced safety profiles for further cancer therapeutic developments.